Biomarin Pharmaceutical Inc BMRN
News
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
BioMarin Announces New R&D and Business Development Leadership
BioMarin to Host 2024 Investor Day on September 4th in New York
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET
Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion
CrowdStrike, KKR and GoDaddy to join S&P 500
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme — Update
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme
BioMarin Pharmaceutical's Achondroplasia Treatment Gets FDA Approval for All Pediatric Patients